← Back to patent-cliff list
Tetrachlorodecaoxide
Tier C — Watch / tradeTetrachlorodecaoxide
Nuvox Pharma LLC
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：M130
Brand：Immunokine, WF10, Oxoferin
Indications (approved)：Allergic rhinitis, Inflammatory disease
Regional status
US
Discontinued
1999-11-02
EU
No progress
2010-03-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tetrachlorodecaoxide?
Approved indications include: Allergic rhinitis, Inflammatory disease.
When does the Tetrachlorodecaoxide patent expire?
No public expiry year is available for Tetrachlorodecaoxide yet; this page updates once verified.
How do I get a quote for Tetrachlorodecaoxide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27